Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
The patented product, developed by Venus Medicine Research Centre (VMRC) for the treatment of multidrug-resistant (MDR) infections, was sold to Cipla in 2019
The partnership also allows both companies to explore CR-001 and SKB105 as monotherapies and in combination
The topical fluralaner solution is cleared for the prevention and treatment of new world screwworm infestation
Terray and BMS aim to accelerate small molecule drug discovery by harnessing EMMI’s integrated experimental and AI capabilities
AEF0217 is a first-in-class CB1 receptor signaling-specific inhibitor
Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Here's a development that aims to keep your blood pressure in check. Literally!
LYMPHIR addresses a clear clinical need in a disease with limited treatment options
The company also revealed that MK-2214 has received Fast Track Designation from the U.S. Food and Drug Administration
Subscribe To Our Newsletter & Stay Updated
